Primary cutaneous follicle center lymphoma of the breast: Management of an exceedingly rare malignancy

Nikolaos S. Salemis1,2,3,*, Nikolaos Koliarakis4, Kyriakos Spiiliopoulos5, Konstantina Kimpouri3, Leonidas Marinos6

1 Breast Cancer Surgery Unit, Army General Hospital, Athens, Greece; 2 IASO Women's Hospital, Athens, Greece; 3 IASO Thessalias Hospital, Larissa, Greece; 4 Department of Radiation Oncology, Andreas Syggros Hospital of Dermatology and Venereology, Athens, Greece; 5 Department of Thoracic and Cardiovascular Surgery, Larissa University Hospital, Larissa, Greece; 6 Department of Haematopathology, Evaggelismos General Hospital, Athens, Greece.

SUMMARY

Primary cutaneous follicle center lymphoma (PCFCL) is defined as a low-grade B-cell non-Hodgkin's lymphoma, which primarily occurs and remains confined to the skin, without evidence of extracutaneous or systemic involvement at the time of diagnosis. PCFCL affecting the breast skin is an exceedingly rare entity with only two cases reported in the English literature. We present a case of PCFCL affecting the periareolar breast skin and review the relevant literature. Our patient was a 64-year-old female who presented with an erythematous plaque in the periareolar region of the left breast. The diagnosis of PCFCL was confirmed by a biopsy performed with a seven-month delay, as the tumor had been initially misdiagnosed as a benign lesion. The patient was successfully treated with local radiation therapy. PCFCL is an indolent lymphoma associated with an excellent prognosis. For localized lesions, skin-directed therapies mainly consisting of radiation therapy or complete surgical excision are curative therapeutic approaches, while systemic chemotherapy should be reserved for patients with extensive disease. This case highlights the need to consider PCFCL as an important differential diagnosis in patients presenting with non-resolving erythematous breast skin lesions. A timely biopsy should be obtained to avoid delays in the initiation of appropriate treatment.

Keywords

PCFCL, cutaneous, lymphoma, follicle, center, breast
time of diagnosis. It most commonly occurs in patients in their fifth to seventh decades of life at a median age of 50 years, with a male to female ratio of 1.5:1 (4,5).

The most common clinical presentation of PCFCL is a solitary or less commonly multiple firm erythematous or violaceous papules, plaques, or tumors of variable size and a smooth surface (6). The lesions tend to enlarge slowly and may reach several centimeters in size. The most commonly affected areas are the head and neck, and the trunk (3-5,7). Multiple lesions are reported in 60% of the patients, 30-40% of which tend to occur in a localized area (8). Histologically, PCFCL is characterized by dense dermal infiltration of large centrocytes derived from germinal center B cells in a follicular, diffused, or mixed growth pattern (8). The neoplastic infiltrate spares the epidermis from which is separated by a grenz zone (7,8).

On immunohistochemical analysis, the neoplastic lymphocytes express B-cell markers such as CD19, CD20, CD22, CD79A, and PAX5 and at least one follicle center marker which is BCL-6 and less commonly CD10 (8,9).

The differentiation of PCFCL from systemic follicular lymphoma (SCFL) is of paramount importance (1) since the two entities require different treatments (7).

The diagnosis of PCFCL is confirmed by an excisional on punch biopsy and subsequent thorough pathologic and immunohistochemical analysis. After the diagnosis of PCFCL is confirmed, a thorough staging investigation is mandatory to rule out extracutaneous involvement.

The treatment options for PCFCL depend on the extent of the disease and include local or systemic treatment. For solitary lesions, radiation therapy and complete surgical excision constitute curative therapeutic approaches (6,8). Surgical resection is considered for small well-demarcated solitary lesions (6).

Complete remission of PCFCL after radiation therapy is reported in up to 100% of the cases (5), whereas recent publications suggest that PCFCL can be successfully treated, with significantly lower doses of radiotherapy (8).

The prognosis of patients with PCFCL is excellent...
even in cases with multifocal or recurrent disease, with a 5-year disease specific survival over 95% (4,5,7,8). Approximately 30% of the patients may exhibit a relapse (5). The extracutaneous spread most commonly involves the regional nodes and the bone marrow (8).

PCFCL may become locally aggressive if left untreated, whereas transformation to diffuse large B cell lymphoma has been suggested (10).

Although PCFCL involving the breast skin is exceedingly rare, a biopsy is indicated in any periareolar skin changes that do not resolve with topical treatment. Temporary resolution of the skin changes with or without topical treatment may occur, resulting in a delayed biopsy. A repeated biopsy should be considered in selected cases with discordance between clinical and pathological findings (9). In our patient, the biopsy was performed with a seven-month delay, as the tumor had been initially misdiagnosed as a benign lesion at another institution.

In conclusion, we present an exceedingly rare case of PCFCL affecting the periareolar breast skin. PCFCL is a clinical entity associated with an indolent clinical course and an excellent prognosis. A timely biopsy of any breast erythematous skin change that does not respond to local therapy should always be considered to avoid delays in initiating appropriate treatment.

Funding: None.

Conflict of Interest: The authors have no conflict of interest to disclose.

References